Shots:

• Gristone to receive $60M at closing- including $30M up front and a $30M as an equity investment at a premium and is eligible to receive up to ~$725M as option exercise payments and milestones along with royalties on sales of therapy
• Gilead will be in charge of conducting a P- I study for the vaccine and will hold an exclusive option to obtain a license to develop & commercialize the HIV-specific therapeutic vaccine beyond P-I study
• The collaboration will utilize Gritstone’s prime-boost vaccine platform which includes self-amplifying mRNA (SAM) and adenoviral vectors with antigens developed by Gilead

 ­ Ref: Gristone | Image: Gilead